eMed

eMed is an app that provides access to healthcare solutions.  eMed was founded in 2020.

eMed, an independently operating subsidiary of Cedara Software, is a digital health company that provides at-home healthcare testing. The company offers specialized treatment programs that are supervised and guided online by eMed Certified Guides for conditions and diseases such as weight loss, Lyme disease, Covid-19, strep, and urinary tract infections. eMed additionally offers at-home testing kits for the conditions and diseases it treats, which are paired with telehealth consultations to assist and verify testing along with prescribing medication for same-day delivery.

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

eMed commences tender offer for Science 37

eMed, an independently operating subsidiary of Cedara Software, is a digital health company that provides at-home healthcare testing. The company offers specialized treatment programs that are supervised and guided online by eMed Certified Guides for conditions and diseases such as weight loss, Lyme disease, Covid-19, strep, and urinary tract infections. eMed additionally offers at-home testing kits for the conditions and diseases it treats, which are paired with telehealth consultations to assist and verify testing along with prescribing medication for same-day delivery.As of January 2024, the company charged users USD 69.99–99.99 for testing kits, which includes the cost of the virtual consultation with the associated specialist. Additionally, the company offers its weight loss program on a subscription basis, charging users USD 99+ per month for access to prescribed weight loss medication (if users are eligible), quarterly blood work, monthly clinician visits, weekly check-ins for medication, and weekly reports on the user's biological changes.In August 2023, eMed acquired Babylon MD’s UK-based subsidiary, Babylon Health Services, for an undisclosed amount. The acquisition was carried out after Babylon MD declared bankruptcy.Most recently, in January 2024, eMed also acquired Science 37, a clinical research specialist, for ∼USD 38 million. The acquisition was aimed at bolstering Science 37’s capabilities in accessing unique patients, accelerating study enrollments, and ensuring the company’s long-term sustainability. Key customers and partnerships As of January 2024, the company noted it had partnered with the National Health Service NHS, Bupa (the largest private medical insurer in the UK), and an unnamed Canadian telecom company to provide digital-first primary care to customers in both the private and public sectors.

<div>
 
 Nice Healthcare is a US based telehealth company with a focus on primary care services to business-to-business (B2B) clients. Once the employer signs its employees with Nice (at a cost of USD 30 to USD 36 per employee per month), employees do not have to incur out of pocket expenses for Nice services and can schedule virtual or home visits within the time frames specified by the company. It connects patients with practitioners through a mobile app over video calls or text messages. Members can also request home visits which will be completed within a few hours, as claimed by the company. As of March 2022, Nice was operating in twelve states, and had over 400 small and medium enterprises (SMEs).
 
 
 In March 2022, the company raised USD 30 million in Series A financing led by DNA Capital which has been earmarked to expand its platform&rsquo;s reach among small and medium businesses. Additionally, the company is hiring three members for its management team to support the continuing growth of the organization.
 
 
 
</div>

Nice Healthcare

Amicomed is a cloud-based Software-as-a-Service (SaaS) platform which provides blood pressure monitoring services. It collects blood pressure data of patients from at-home devices, applies algorithms, and assesses the fluctuations in the blood pressure. Physicians can be connected and provided with blood pressure data of their patients in order to facilitate their workload, enabling more personalized management of patients regarding medication and lifestyle indications.Amicomed can also recommend actionable and personalized lifestyle interventions such as daily diet and exercises via virtual coaching.

Amicomed

Winston is a men’s health telemedicine platform that treats common issues impacting men such as sexual problems, hair loss, acne, and cold sores. Winston allows patients to consult doctors, place orders for prescription drugs, and offers free delivery to the homes of patients.The Toronto-based company aims to avoid men deferring doctor visits or withholding sensitive information. The consultation fee is covered by the provincial health plan, but the prescriptions are billed to the customer.

Winston

<div>
 
 Dialogue partners with employers and health insurers to offer telehealth services to their employees and members. The users have 24/7 access to doctors, nurses, and other healthcare professionals via audio, video, and chat options for wide arrays of physical and mental health needs, artificial intelligence-enabled (AI-enabled) triage, referrals, and prescription renewals. 
 
 
 The company launched its trademarked Integrated Health Platform in January 2021 to consolidate its virtual care, wellness programs, mental healthcare services, and Employee Assistance Program (EAP) onto a single platform. The company claims to be the only integrated health and wellness B2B platform in Canada. 
 
 
 Key Customers and partnerships
 
 
 Dialogue had direct relationships with over 2,000 customers across Canada and Germany as of December 2020 and served around 50,000 organizations through these partnerships. In addition, the number of members with access to the virtual platform topped 1 million in January 2021. 
 
 
 Fundings and financials
 
 
 As of March 2021, Dialogue was planning to raise CAD 100 million (USD 80 million) from an initial public offering that will be listed on the Toronto Stock Exchange under the ticker symbol &ldquo;CARE.&rdquo; 
 
 
 In Q2 2023, net losses reduced significantly YoY to CAD 5.8 million (USD 4.3 million) from CAD 8.4 million (USD 6.3 million) in Q2 2022. Top-line revenue met internal expectations, growing 17.2% YoY to CAD 25.5 million (USD 19.0 million), driven by &nbsp;an increase in new members (by 18.6% YoY), 
 an expansion of the attach rate as existing customers added more services, and full-quarter contributions from Tictrac.
 
 Dialogue Health has not provided any forward-looking guidance as the company has entered into an agreement to be 
 <a href="https://investors.dialogue.co/English/news/news-details/2023/Dialogue-to-be-Acquired-by-Sun-Life/default.aspx">
 acquired by financial services company Sun Life Financial
 </a>
 for a consideration of CAD 365 million (USD 270 million) or CAD 5.15 (USD 3.82) per share. The transaction is expected to close in Q4 2023. Post acquisition, Dialogue will delist from the Toronto Stock Exchange but will continue to operate as a standalone entity under the &ldquo;Sun Life Canada&rdquo; brand from its head office in Qu&eacute;bec. 
 
 
 
</div>

Dialogue

Grin offers telemedicine and remote monitoring services for orthodontic needs such as braces and teeth straightening. Patients can conduct self-scans (using a Grin device made available to patients in collaboration with 3M) which can be connected to their smartphones and share the feed with orthodontists to access dental solutions. The company plans to go to a subscription-based model after the pandemic. The app also encourages patients to have a 40-second check monthly and share the scan with a dentist in order to allow patients to regularly maintain their dental hygiene.Grin is the only Telehealth disruptor covered on the hub that provides virtual orthopaedic consultations.Funding and financialsIn April 2021, the New York-based teledental platform concluded a seed funding of USD 14 million, and the funds will be allocated to develop additional functionalities by building out its technology. The proceeds will also be used to scale up its team, expand its geographic footprint, and add doctors to the company’s orthodontic partner network.

Grin

Real-time collection of patients’ health-related data using any remote patient monitoring device combined with general telemedicine services to reduce readmission rates. 


A platform that facilitates the transmission of patient data to different locations for further evaluation and interpretation by medical specialists. 


A digital platform that offers specialty care services to address the specific needs of a patient or demographic, including consultations where patients are generally reluctant to meet practitioners face-to-face.

Primary care through virtual consultations for general health-related concerns using a digital platform or mobile app. 

Companies developing B2B software solutions for patient engagement, care navigation, practice management, and electronic health records integration to facilitate telehealth services for healthcare providers. 

IoT is used by most telehealth providers to operate virtual services

All telehealth players are involved in digital health via virtual offerings

Industry players offer varying degrees of personalization for each target audience

Some players offer technology and platforms to healthcare providers, converting physical-only services into virtual services

Specific telehealth offerings focus on diversity and inclusion, providing care to LGBTQ+ or BIPOC populations

Generative AI is used to streamline administrative tasks such as clinical note-taking

ANALYST_QUICK_TAKE

<div>
 Science 37, a clinical research specialist, is set to merge with eMed, a virtual care and treatment service provider. Valued at approximately USD 38 million, an all-cash deal will have eMed acquire all shares of Science 37 at a premium of 21.3%. The merger should bolster Science 37's patient access, speed up study enrollments, and solidify long-term sustainability. Post-merger, Science 37 will become privately held. eMed offers at-home healthcare tests and specialized treatment programs for conditions like weight loss, Lyme disease, and Covid-19, and supplies testing kits paired with telehealth consultations.
</div> Analyst QuickTake : Science 37 initially went public via a Special Purpose Acquisition Company (SPAC) deal in October 2021 and was valued at more than USD 1 billion at the time. The company’s sharp drop in value is attributable to two main factors: Unrecognized revenue associated with backlogs and cancellations and the inability to secure contracts outside of the US. This transaction marks the second eMed has completed in a 12 month period, with its UK arm previously having <a href="https://sp-edge.com/updates/21451"> acquired Babylon Health’s </a> failing UK-based operations for an undisclosed sum.&nbsp;

eMed

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless